After being beaten down for the past two years due to the biotech industry getting crushed, CRISPR Therapeutics is emerging as a company with a breakthrough curative treatment of Sickle Cell Disease. While the SCD treatment has potential for several billion in revenue annually (company estimates 30k patients with an immediate need for the treatment in the US/EU) once fully adopted, the real opportunity here is being first to market with a gene editing treatment.
If CRSP proves its long term safety and efficacy here, the path to curing cardiovascular diseases and blood disorders (next up in the product pipeline along with oncology) is wide open and will only speed up the FDA approval and public acceptance process.
With a market cap under 5b, 1.8b in cash (plus 200m for its approval milestone payment today), the balance sheet is strong to support continued R&D and increase distribution capacity.
They also have a partnership with large cap Vertex VRTX to help commercialize Exa-cel.
I’m invested as I see this as the 2019 Tesla of CRISPR and gene editing.
Leave a Reply